Barclays PLC reiterated their hold rating on shares of Celgene Corporation (NASDAQ:CELG) in a report published on Friday morning. Barclays PLC currently has a $135.00 target price on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Jefferies Group LLC set a $154.00 price objective on Celgene Corporation and gave the company a buy rating in a research report on Saturday, May 13th. Vetr lowered Celgene Corporation from a strong-buy rating to a buy rating and set a $132.90 price objective on the stock. in a research report on Thursday, May 11th. BTIG Research reiterated a buy rating and set a $138.00 price objective on shares of Celgene Corporation in a research report on Monday, May 1st. Cantor Fitzgerald set a $159.00 price objective on Celgene Corporation and gave the company a buy rating in a research report on Thursday, April 27th. Finally, Cann reiterated a buy rating on shares of Celgene Corporation in a research report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $146.02.

Shares of Celgene Corporation (NASDAQ CELG) opened at 135.41 on Friday. The firm has a market capitalization of $105.94 billion, a price-to-earnings ratio of 41.94 and a beta of 1.89. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00. The stock’s 50 day moving average price is $131.55 and its 200-day moving average price is $123.19.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s revenue was up 18.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.44 EPS. Equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.

WARNING: “Barclays PLC Reaffirms Hold Rating for Celgene Corporation (CELG)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/barclays-plc-reaffirms-hold-rating-for-celgene-corporation-celg/1464949.html.

In related news, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the transaction, the insider now owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 227,755 shares of company stock valued at $30,368,142. 0.95% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Diversified Trust Co raised its position in Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares during the period. Sowell Financial Services LLC raised its position in Celgene Corporation by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 13 shares during the period. South Texas Money Management Ltd. raised its position in Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 15 shares during the period. Flagship Harbor Advisors LLC raised its position in Celgene Corporation by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 18 shares during the period. Finally, Keel Point LLC raised its position in Celgene Corporation by 0.9% in the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 28 shares during the period. 78.39% of the stock is owned by institutional investors.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.